RainDance Technologies secures $35m in financing

RainDance Technologies Inc., a Billerica company developing genomic tools for the ultra-sensitive detection of cancer and inherited diseases, said Monday that it has closed a structured debt financing with Capital Royalty Partners L.P.

The transaction provides RainDance with up to $35 million to support commercial expansion of the company’s Digital PCR and Next-Generation Targeted DNA Sequencing products, the company said in a press release.

The financing builds on RainDance’s $20 million Series E equity financing announced in April.

“RainDance has perfected its proprietary droplet technology to deliver highly sensitive, non-invasive analysis from complex biological samples, which has profound implications for human medicine,’’ Luke Duster of Capital Royalty said in a statement. “The company has unparalleled technology, which is being rapidly adopted by industry leaders, for early detection and disease research in areas of oncology, pathogen surveillance, and inherited diseases.’’

Advertisement

Loading Comments...